Brought to you by 
Mayo Clinic, Cancer Genetics form biomarker JV OncoSpire Genomics
12 Dec 2013
Executive Summary
Following two years of discussions, the Mayo Clinic and newly public Cancer Genetics Inc. (DNA-based cancer diagnostics) have formed the joint venture, OncoSpire Genomics, which has been tasked with discovering and commercializing new cancer tests that will utilize next-generation sequencing.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mayo Clinic, Cancer Genetics form biomarker JV OncoSpire Genomics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice